AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy ...

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Switzerland-based HAYA Therapeutics, a biotech developing precision RNA-guided regulatory genome targeting therapeutics that ...

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.

"The positive results for Imfinzi in the Potomac trial represent a significant advance that will potentially allow more patients with early-stage bladder cancer to benefit from this important ...

Pharma giant AstraZeneca has reported positive results from a Phase III trial of its treatment for non-muscle-invasive ...